NL-OMON45265已完成3 期
A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD) - CS 100
Clinical Research0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Subject is 22 * 75 years of age at the time of informed consent
- •Subject with documented symptoms of GERD for longer than 6 months (regurgitation and/or heartburn which is defined as burning epigastric or substernal pain which responds to acid neutralization or suppression) which requires daily use of proton pump inhibitors (PPIs) or other antireflux drug therapy, who continue to have symptoms despite maximum medical therapy or are *intolerant* severe
- •sideeffects (e.g. anaphylaxis or severe allergic reaction, recurrent C. difficile, severe hypomagnesaemia) to one PPI or mild/moderate side effect (e.g.
- •nausea, vomiting, diarrhea or abdominal pain) to at least 2 PPIs of different chemical classes. Subjects with symptomatic improvement on PPI therapy demonstrated by a composite GERDHRQL score of *20 off PPI, and with *10 point improvement on PPI when comparing to their off PPI composite GERDHRQL score.
- •Subject has exhibited excessive lower esophageal acid exposure during pH monitoring (defined as distal esophageal pH < 4 for > 6.0% of the monitoring time) performed after at least 5 days off of PPIs and at least 2 days off of H2 blockers.
- •Subject has esophagitis * Grade B (LA classification) as measured by upper endoscopy off PPI and H2 blockers for at least 10 days.
排除标准
- •Exclusion Criteria
- •Subjects must not meet any of the following study exclusion criteria:
- •a. Subject had a previous EndoStim LES System implant and/or implant attempt
- •b. Subject underwent previous surgery involving the gastroesophageal junction or the lead implant site, such as a Nissen fundoplication
- •c. Subject underwent previous endoscopic intervention for the treatment of GERD and/or Barrett*s esophagus
- •d. Subject has a hiatal hernia larger than 3 cm as determined by endoscopy
- •e. Subject has history of gastroparesis
- •f. Subject has any nonGERD esophageal motility disorders that in the opinion of investigator precludes an antireflux procedure
- •g. Subject has history of or known esophageal stricture or significant esophageal anatomic abnormalities (obstructive lesions, etc.)
- •h. Subject has Barrett*s esophagus or any grade of dysplasia
- •i. Subject has documented history of esophagitis Grade C or D (LA Classification)
- •j. Subject has a history of suspected or confirmed esophageal or gastric cancer
- •k. Subject has esophageal or gastric varices
- •l. Subject has symptoms of dysphagia more than once per week every week within the last 3 months
- •m. Subject is unable to tolerate withdrawal from H2 Blockers or PPI medications
- •n. Subject has suspected or known allergies to titanium, platinum, iridium, stainless steel, silicone, epoxy, or nylon
- •o. Subject has a body mass index (BMI) > 35 kg/m2
- •p. Subject has any significant multisystem diseases
- •q. Subject has an autoimmune or a connective tissue disorder (scleroderma, dematomyositis, CalcinosisRaynaud*sEsophagus Sclerodactyly Syndrome (CREST), Sjogren*s Syndrome, Sharp*s Syndrome, etc.) requiring therapy in the preceding 2 years
- •r. Subject has Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c > 9.5 in the previous 6 months or at screening/baseline
- •s. Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease (i.e. unstable angina pectoris, hemodynamically significant valvular disease, severe congestive heart failure), or any cardiac therapeutic intervention within the last 6 months.
- •t. Subject has had a significant cerebrovascular event within the last 6 months
- •u. Subject has an existing implanted electrical stimulator (pacemaker, implantable cardioverter defibrillator, DBS, bone growth or pelvic floor stimulators, drug pumps, etc.)
- •v. Female subject of childbearing potential and is pregnant or nursing, or intends to become pregnant during the trial period, who is not using a reliable form of birth control
- •w. Subject is currently enrolled in other potentially confounding research
- •x. Subject has an active infection as determined by the investigator
- •y. Subject has a history of any malignancy in the last 2 years
- •z. Subject has a life expectancy less than 3 years
- •aa. Subject has a diagnosed major psychiatric disorder (bipolar, schizophrenia, etc.)
- •bb. Subject has any condition that, at the discretion of the investigator or sponsor, would interfere with accurate interpretation of the study endpoints or preclude participation in the trial
研究者
相似试验
招募中
Unknown
Study using the App for Tinnitus Treatment in Patients with Tinnitus.Chronic tinnitus with associated sufferingJPRN-jRCTs032230359Wasano Koichiro60
招募中
Unknown
Investigation of improvement in cognitive function after transcranial direct current stimulation in mild cognitive impairmentMental and behavioural disordersKCT0009708Ybrain190
尚未招募
Unknown
A multicenter, randomized, double-blind, sham-controlled, Superiority, confirmatory clinical trial to evaluate the safety and effectiveness of a Clickless DTx digital therapy device for patients diagnosed with temporomandibular disorders (TMD)KCT0009493Beyondmedicine102
进行中（未招募）
不适用
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients with SchizophreniaMedDRA version: 14.1Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2011-004889-15-FIJanssen-Cilag International N.V.1,288
进行中（未招募）
1 期
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients with SchizophreniaSchizophreniaEUCTR2011-004889-15-SKJanssen-Cilag International N.V.1,429